Matthew W Foehr - Net Worth and Insider Trading
Matthew W Foehr Net Worth
The estimated net worth of Matthew W Foehr is at least $34 Million dollars as of 2024-04-27. Matthew W Foehr is the President and CEO of OmniAb Inc and owns about 2,908,803 shares of OmniAb Inc (OABI) stock worth over $13 Million. Matthew W Foehr is the President and COO of Ligand Pharmaceuticals Inc and owns about 173,354 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $12 Million. Matthew W Foehr is also the Director of Viking Therapeutics Inc and owns about 111,250 shares of Viking Therapeutics Inc (VKTX) stock worth over $8 Million. Besides these, Matthew W Foehr also holds Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) . Details can be seen in Matthew W Foehr's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Matthew W Foehr has not made any transactions after 2024-03-22 and currently still holds the listed stock(s).
Transaction Summary of Matthew W Foehr
Matthew W Foehr Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew W Foehr owns 6 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Viking Therapeutics Inc (VKTX) , and Ritter Pharmaceuticals Inc (RTTR) among others .
Click here to see the complete history of Matthew W Foehr’s form 4 insider trades.
Insider Ownership Summary of Matthew W Foehr
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
LGND | Ligand Pharmaceuticals Inc | 2022-05-13 | EVP and COO |
VKTX | Viking Therapeutics Inc | 2022-05-02 | director |
RTTR | Ritter Pharmaceuticals Inc | 2020-01-21 | director |
QLGN | Qualigen Therapeutics Inc | 2015-06-24 | director |
AHPA | Avista Public Acquisition Corp II | 2022-11-01 | director & President & CEO |
OABI | OmniAb Inc | 2024-03-22 | director & President & CEO |
Matthew W Foehr Latest Holdings Summary
Matthew W Foehr currently owns a total of 5 stocks. Among these stocks, Matthew W Foehr owns 2,908,803 shares of OmniAb Inc (OABI) as of March 22, 2024, with a value of $13 Million and a weighting of 38.86%. Matthew W Foehr owns 173,354 shares of Ligand Pharmaceuticals Inc (LGND) as of May 13, 2022, with a value of $12 Million and a weighting of 36.48%. Matthew W Foehr also owns 111,250 shares of Viking Therapeutics Inc (VKTX) as of May 2, 2022, with a value of $8 Million and a weighting of 24.65%. The other 2 stocks Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Matthew W Foehr
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
OABI | OmniAb Inc | 2024-03-22 | 2,908,803 | 4.48 | 13,031,437 |
LGND | Ligand Pharmaceuticals Inc | 2022-05-13 | 173,354 | 70.57 | 12,233,592 |
VKTX | Viking Therapeutics Inc | 2022-05-02 | 111,250 | 74.31 | 8,266,988 |
RTTR | Ritter Pharmaceuticals Inc | 2018-08-17 | 2,190 | 0.45 | 986 |
CNCT | China Teletech Holding Inc | 2003-05-14 | 14 | 0.00 | 0 |
Holding Weightings of Matthew W Foehr
Matthew W Foehr Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 9 transactions in OmniAb Inc (OABI) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 225,000 shares on March 22, 2024, which cost Matthew W Foehr around $1 Million.
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 1 buys and 6 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 2,500 shares on May 13, 2022, which cost Matthew W Foehr around $206,900.
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 3 transactions in Viking Therapeutics Inc (VKTX) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Viking Therapeutics Inc is the acquisition of 45,000 shares on May 2, 2022, which cost Matthew W Foehr around $111,150.
More details on Matthew W Foehr's insider transactions can be found in the Insider Trading History of Matthew W Foehr table.Insider Trading History of Matthew W Foehr
- 1
Matthew W Foehr Trading Performance
GuruFocus tracks the stock performance after each of Matthew W Foehr's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew W Foehr is 3.95%. GuruFocus also compares Matthew W Foehr's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew W Foehr within 3 months outperforms 13 times out of 24 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Matthew W Foehr's insider trading performs compared to the benchmark.
Performance of Matthew W Foehr
Average Return
61.87%
Outperforming Transactions
68%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 1.6 | 3.95 | 5.66 | 61.87 | 36.82 | 18.96 |
Relative Return to S&P 500(%) | 0.73 | 0.73 | 0.01 | 53.03 | 26.83 | 9.31 |
Matthew W Foehr Ownership Network
Ownership Network List of Matthew W Foehr
Ownership Network Relation of Matthew W Foehr
Matthew W Foehr Owned Company Details
What does Ligand Pharmaceuticals Inc do?
Who are the key executives at Ligand Pharmaceuticals Inc?
Matthew W Foehr is the EVP and COO of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and CEO & President John L Higgins .
Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary
Over the past 18 months, Matthew W Foehr made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 8,301 shares made by Stephen L Sabba .
In summary, during the past 3 months, insiders sold 2,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 2,033 shares. During the past 18 months, 41,289 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 37,289 shares.
Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ligand Pharmaceuticals Inc Insider Transactions
Matthew W Foehr Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew W Foehr. You might contact Matthew W Foehr via mailing address: 11119 North Torrey Pines Rd #200, La Jolla Ca 92037.